Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer

Figure 8

Association between the risk model and gemcitabine chemoresistance in pancreatic cancer (PC). (a) Enrichment analysis showed 5 of 6 prognosis-associated differentially expressed metabolic genes (PAGs) were involved in “drug metabolism or response to drug.” (b) Gemcitabine-resistant pancreatic cancer cell lines (CFPAC-1 and HPAFII) had higher risk scores than the parental group ( value <0.001). (c) The expression levels of several gemcitabine metabolism-associated chemoresistance genes between high-risk and low-risk groups in TCGA cohort. Higher expressions of CDA ( value = 0.001) and RMM2 ( value = 2.517-12) were found in the high-risk group.

(a)

(b)

(c)